medigraphic.com

2013, Number 9

<< Back Next >>

waxapa 2013; 5 (9)

Análisis de sobrevida de los pacientes con cáncer de células renales en tratamiento con sunitinib en la caja costarricense de seguro social en el periodo 2007 al primer semestre del 2012

Ching FSM, Castro CJA

Language: Spanish
References: 18
Page: 5-10
PDF size: 599.87 Kb.


ABSTRACT

Sunitinib, a high cost drug, is used in renal cell carcinoma (RCC) treatment. The aim of the study was to evaluate the clinical response in progression-free survival of patients with renal cell carcinoma in hospitals of the Caja Costarricense de Seguro Social from 2007 to june 2012. Methods: observational, crosssectional, prescription-indication study. A survival analysis was conducted in 48 patients. Outcomes: Global survival was 17.7 months and progression-free survival median was 13.2 months. Patients older than 60 years old had longer survival time than youngers, 14.8 (IC95% 13.15-16.39): 10.8 (IC95% 8.57- 13.10). Conclusion: progression-free survival showed was longer than one year. Global survival in patients with renal cell carcinoma exposed to sunitinib was longer than reported in clinical trials.


REFERENCES

  1. 1.Food and Drug Administration. Drug Approval Package. Sutent (Sunitinib Malate) Capsules. [Internet]. 2006 Abril. Disponible en: http:// www.accessdata.fda.gov/drugsatfda_docs/ nda/2006/021938s000_021968s000_Stutent.cfm.

  2. 2.Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferón alfa in metastatic renal-cell carcinoma. N Engl J Med [Internet]. 2007 ene 11; 356(2):115-

  3. Disponible en: http://www.ncbi.nlm.nih.gov/ pubmed/17215529.

  4. 3.Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Onco [Internet], 2006 ene 1; 24(1):16-24. Disponible en: http://www.ncbi.nlm.nih. gov/pubmed/16330672.

  5. 4.Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol [Internet]. 2007 Mar 1;25(7):884-896. Disponible en: http:// www.ncbi.nlm.nih.gov/pubmed/17327610.

  6. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol [Internet]. 2006 ene 1 ;24(1):25- 35. Disponible en: http://www.ncbi.nlm.nih.gov/ pubmed/16314617.

  7. 6.Gore ME, Szczlik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol [Internet]. 2009 Aug;10(8):757-763. Disponible en: http://www.ncbi. nlm.nih.gov/pubmed/19615940.

  8. National Institute for Health and Clinical Excellence (NICE).Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. Technology appraisal guidance 169. NSH [Internet]. 2011 Feb 4. Disponible en: http://www.nice.org.uk/ TA169.

  9. 8.OMS. Cómo investigar el uso de medicamentos en los servicios de salud. Indicadores seleccionados del uso de medicamentos. Ginebra: Organización Mundial de la Salud. 1993 (Serie sobre investigaciones, Nº 07).Disponible en: http://apps. who.int/medicinedocs/en/d/Jh2975s/1.html.

  10. 9.Laporte JR, Tognoni G. Estudios de utilización de medicamentos y de farmacovigilancia. En: Laporte JR, Tognoni G,editores. Principios de Epidemiología del Medicamento. 2 ed. Barcelona: Masson-Salvat; 1993. p.1-23.

  11. Capellà D, Laporte JR. Métodos aplicados en estudios descriptivos de utilización de medicamentos. En: Laporte JR, Tognoni G, editores. Principios de Epidemiología del Medicamento. 2 ed. Barcelona: Masson-Salvat; 1993. p.67-92

  12. Ljungberg B, Campbell SC, Choi HY, Cho HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA. The epidemiology of renal cell carcinoma. Eur Urol. 2011 Oct; 60(4):615-21.

  13. Chow WH, Gridley G, Fraumeni JF Jr, Järvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343(18):1305.

  14. Choi MY, Jee SH, Sull JW, Nam CM. The effect of hypertension on the risk for kidney cancer in Korean men. Kidney Int. 2005;67(2):647.

  15. 14.Weikert S, Boeing H, Pischon T, Weikert C, Olsen A, Tjonneland A,et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol. 2008;167(4):438.

  16. Vatten LJ, Trichopoulos D, Holmen J, Nilsen TI. Blood pressure and renal cancer risk: the HUNT Study in Norway. Br J Cancer. 2007;97(1):112.

  17. Flaherty KT, Fuchs CS, Colditz GA, Stampfer MJ, Speizer FE, Willett WC, Curhan GC. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control. 2005;16(9):1099.

  18. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16(6):2261.




2020     |     www.medigraphic.com